6505--Teriparatide Injection (VA-26-00049896)

The Department of Veterans Affairs is seeking to procure Teriparatide Injection (250mcg/mL, 560mcg) in pen form through an unrestricted commercial item solicitation under FAR Part 12, with the goal of ensuring an uninterrupted supply for the VA, Department of Defense, Bureau of Prisons, and Indian Health Service. The solicitation, numbered 36E79726R0020, was posted on May 4, 2026, and responses are due by May 19, 2026, at 2:30 PM Central Time, submitted exclusively through SAM.gov. The contract structure includes a one-year base period with four additional one-year option periods, all pre-priced and exercisable at the government’s discretion. Offerors must supply the product with its exact labeled name and provide a unique National Drug Code (NDC) for each submission, with an estimated annual requirement of 39,038 pens. The place of performance is HINES, IL, with distribution managed through the VA and DOD Pharmaceutical Prime Vendor Programs. Award will be made to the responsible offeror capable of providing a continuous, reliable supply, with the approach aligning with a Lowest Price Technically Acceptable methodology, though not explicitly stated. The contracting office, located at the OPAL/National Acquisition Center in HINES, IL, is managed by Contract Specialist Billy Fong, who serves as the primary point of contact. The acquisition is classified under NAICS code 325412 for Pharmaceutical Preparation Manufacturing, and the product must be FDA-approved and commercially available without modification. No specific packaging, labeling, inspection location, or FOB shipping terms are detailed in the solicitation, though compliance with federal labeling and NDC standards is required. There is no set-aside for small businesses or socioeconomic categories, and no representations, certifications, or socioeconomic declarations are required from offerors beyond standard SAM.gov registration. The solicitation does not include detailed evaluation factors, contract clauses, or attachments, and payment, invoicing, and accounting details such as appropriation codes or remittance instructions are not specified, although invoicing is expected to occur through the Pharmaceutical Prime Vendor Programs. The contracting office does not designate a separate COR/COTR or PCO beyond Billy Fong, and no additional special requirements, security clearances, or OCI provisions are included. Offerors must adhere to electronic submission protocols via SAM.gov without paper submissions permitted.